[2,2,6,6-tetramethyl-4-(3-{[methyl(prop-2-yn-1-yl)amino]methyl}benzamido)piperidin-1-yl]oxidanyl

ID: ALA5283202

Max Phase: Preclinical

Molecular Formula: C21H30N3O2

Molecular Weight: 356.49

Names and Identifiers

Canonical SMILES:  C#CCN(C)Cc1cccc(C(=O)NC2CC(C)(C)N([O])C(C)(C)C2)c1

Standard InChI:  InChI=1S/C21H30N3O2/c1-7-11-23(6)15-16-9-8-10-17(12-16)19(25)22-18-13-20(2,3)24(26)21(4,5)14-18/h1,8-10,12,18H,11,13-15H2,2-6H3,(H,22,25)

Standard InChI Key:  JMBHPIIINCMWLR-UHFFFAOYSA-N

Molfile:  

 
     RDKit          2D

 26 27  0  0  0  0  0  0  0  0999 V2000
    2.1924    1.1410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1924    0.3160    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9069   -0.0965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.9069   -0.9215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    2.1924   -1.3339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4779   -0.9215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    1.4779   -0.0965    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7634   -1.3339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0489   -0.9215    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6654   -1.3339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.6654   -2.1589    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3799   -2.5715    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0944   -2.1589    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
   -2.0944   -1.3339    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -1.3799   -0.9215    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.9069   -1.4772    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.3766   -0.5587    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -2.8089   -2.5715    0.0000 O   0  0  0  0  0  1  0  0  0  0  0  0
   -1.9102   -3.2034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
   -0.8496   -3.2034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7634   -2.1589    0.0000 O   0  0  0  0  0  0  0  0  0  0  0  0
    1.4779    1.5534    0.0000 N   0  0  0  0  0  0  0  0  0  0  0  0
    1.4779    2.3784    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7634    2.7910    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.0489    3.2034    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
    0.7634    1.1410    0.0000 C   0  0  0  0  0  0  0  0  0  0  0  0
  2  1  1  0
  3  2  1  0
  4  3  2  0
  5  4  1  0
  6  5  2  0
  2  7  2  0
  7  6  1  0
  6  8  1  0
  8  9  1  0
  9 10  1  0
 11 10  1  0
 12 11  1  0
 13 12  1  0
 14 13  1  0
 15 14  1  0
 10 15  1  0
 14 16  1  0
 14 17  1  0
 13 18  1  0
 12 19  1  0
 12 20  1  0
  8 21  2  0
  1 22  1  0
 22 23  1  0
 23 24  1  0
 24 25  3  0
 22 26  1  0
M  RAD  1  18   2
M  END

Alternative Forms

1. Parent:

   

   ALA5283202

   ---

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Calculated Properties

Molecular Weight: 356.49

Molecular Weight (Monoisotopic): 356.2338

AlogP: 2.85

#Rotatable Bonds: 5

Polar Surface Area: 55.48

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: ┄

HBA (Lipinski): 5

HBD (Lipinski): 1

#RO5 Violations (Lipinski): ┄

CX Acidic pKa: ┄

CX Basic pKa: 7.36

CX LogP: 1.96

CX LogD: 1.68

Aromatic Rings: 1

Heavy Atoms: 26

QED Weighted: 0.83

Np Likeness Score: -1.05

References

1. Tripathi AC, Upadhyay S, Paliwal S, Saraf SK..  (2018)  Privileged scaffolds as MAO inhibitors: Retrospect and prospects.,  145  [PMID:29335210] [10.1016/j.ejmech.2018.01.003]

Source

Source(1):

• Scientific Literature